Impact of *Fusobacterium nucleatum* in the gastrointestinal tract on natural killer cells

Yeon Ji Kim, Bu Kyung Kim, Seun Ja Park, Jae Hyun Kim

**ORCID number:** Yeon Ji Kim [0000-0002-3196-0384]; Bu Kyung Kim [0000-0001-7845-4377]; Seun Ja Park [0000-0003-3217-5155]; Jae Hyun Kim [0000-0002-4272-8003].

**Author contributions:** Kim YJ, Kim BK, Park SJ and Kim JH designed the study; Kim YJ performed the experiments; Kim YJ and Kim JH wrote the paper; Kim BK and Park SJ critically reviewed the manuscript for important intellectual content; Kim JH approved the manuscript.

**Supported by** National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT), No. 2017R1C1B5017576.

**Institutional review board statement:** No human experiments were conducted and no human samples were used in this study.

**Institutional animal care and use committee statement:** All experimental procedures were performed with the approval of the Animal Experimentation Ethics Committee of Kosin University College of Medicine, No. KMAP-18-06.

**Conflict-of-interest statement:** The authors declare no conflicts of interest. The authors alone are responsible for the content of this study.

**Abstract**

**BACKGROUND**

Gut microbial dysbiosis contributes to the development and progression of colorectal cancer (CRC). Natural killer (NK) cells are involved in early defense mechanisms to kill infective pathogens and tumor cells by releasing chemokines and cytokines. To better understand the relationship between the gut microbiome and CRC, it was hypothesized here that a high abundance of *Fusobacterium nucleatum* (*F. nucleatum*) in the gastrointestinal tract could cause reduced NK cell activity.

**AIM**

To identify associations between gastrointestinal tract *F. nucleatum* levels and NK cell activity.

**METHODS**

*In vitro* experiments were performed on NK cells treated with *F. nucleatum*, *Peptostreptococcus anaerobius*, and *Parvimonas micra* to identify the effects of gut microbiome species on NK cells. Following 24 and 48 h of treatment, NK cell counts were measured. In parallel studies, C57BL/6 mice were given broad-spectrum antibiotics in their drinking water to reduce resident gut flora. After 3 wk, the mice received the various bacterial species or phosphate-buffered saline (PBS) *via* oral gavage every 2 d for 6 wk. At the study end, blood samples were acquired to perform NK cell activity assessment and cytokine analysis. Intestinal tissues were collected and analyzed *via* immunohistochemistry (IHC).

**RESULTS**

The data show that after 3 wk of broad-spectrum antibiotic treatment, levels of total bacteria and *F. nucleatum* were markedly decreased in mice. Gavage of *F.
**INTRODUCTION**

Increasing evidence indicates that gut microbial dysbiosis contributes to the development and progression of colorectal cancer (CRC) [1-3]. Studies have suggested that the presence of several bacteria, including *Fusobacterium nucleatum* (F. nucleatum), *Peptostreptococcus anaerobius* (P. anaerobius), *Parvimonas micra* (P. micra), and *Solobacterium moorei* are significantly associated with CRC [4,5]. Other studies have described a strong correlation between the presence of *F. nucleatum* (a common oral anaerobic Gram-negative rod that is a typical cause of periodontal disease) with CRC development and pathogenicity [6-8]. The presence of *F. nucleatum* increases the proliferation of CRC cells and tumor development in mice by activating Toll-like receptor 4 signaling to nuclear factor-kappa B, and up-regulating the expression of miRNA-21. Other studies have shown that *F. nucleatum* can suppress the tumor-immune microenvironment in a manner that could inhibit T-cell responses to antigens and arrest human T-cells in the G1 phase or induce apoptotic cell death [9-11]. In one report, the Fap2 protein of *F. nucleatum* was shown to play a crucial role in mediating fusobacterial CRC enrichment by Gal-GalNAc that is over-expressed in CRC. In addition, this protein directly interacts with the inhibitory receptor TIGIT on natural killer (NK) cells, leading to an inhibition of NK cell cytotoxicity in humans [9].

NK cells are large granular lymphocytes (unique type of cytotoxic lymphocyte) that play a role in innate immunity [12]. NK cells are involved in early defense mechanisms to kill infective pathogens and tumor cells by releasing chemokines and cytokines, as well as by helping other immune cells in targeted cell elimination [13]. Imai et al [14] in a follow-up study of 154 patients with cancer for 11 years found that patients with
high cytotoxic activity among their peripheral blood lymphocytes had decreased cancer risk and, conversely, those with low cytotoxic activity had increased cancer risk [14]. In a study that evaluated 140 patients with Stage III CRC who underwent surgery, it was seen that lower pre-operative NK cell activity resulted in significant effects on the development of metachronous distant metastases[15]. A cross-sectional study performed in Canada that evaluated NK cell activity in a high-risk population of subjects screened for CRC (via colonoscopy) showed that subjects with CRC had lower NK cell activity compared to those without CRC[16]. In addition, NK cells have been shown to be deficient when analyzing their localization and densities within CRC tissues[17].

To better understand any relationship between the gut microbiome and CRC, it was hypothesized here that a high abundance of *F. nucleatum* in the gastrointestinal tract could cause reduced NK cell activity. Accordingly, this association would impact upon the development of CRC in a host. To test this hypothesis, associations between the abundance of *F. nucleatum* in the murine gastrointestinal tract and NK cell activity were evaluated.

### MATERIALS AND METHODS

**Bacterial culture**

*F. nucleatum* (ATCC 25586), *P. anaerobius* (ATCC 27373), and *P. micra* (ATCC 33270) were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). All bacteria were cultured at 37°C in Anaerobe basal broth (CM0957, OXOID, Thermo Fisher Scientific, West Palm Beach, FL, USA) in an anaerobic jar (Hardy Diagnostics, Santa Maria, CA, USA). Anaerobic conditions were maintained using AnaeroGen packets (Thermo Fisher Scientific).

**Culture of NK cells**

For *in vitro* studies, NK92 cells (CRL-2407, human NK line) were obtained from ATCC. The cells were cultured in a minimum essential medium (MEM, Sigma, St. Louis, MO, USA) containing 12.5% fetal bovine serum (HyClone, Logan, UT, USA), 12.5% horse serum (HyClone), 200 U recombinant IL-2/mL (Invitrogen, Carlsbad, CA, USA), 2 mmol/L L-glutamine, 0.2 mmol/L myoinositol, 0.1 mmol/L 2-mercaptoethanol, and 0.02 mmol/L folic acid (all Sigma, St. Louis, MO, USA) at 37°C in a 5% CO₂ incubator. Fresh medium was replaced every 2 d; cells reached confluence at 5 d of culture.

**Cell proliferation assay**

Cell viability was determined by trypsin blue exclusion. Here, NK92 cells were plated at 10⁵ cells/well in 6-well plates. The cells were infected with bacteria at 100:1, 250:1, and 500:1 multiplicity of infection (MOI); control cells received phosphate-buffered saline (PBS, pH 7.4). After 24 and 48 h of culture, cell viabilities were assessed.

**Animal experiments**

C57BL/6 mice (male, 6-wk-of-age) were purchased from Orient Bio (Gyeonggi, Korea) and housed in pathogen-free facilities maintained at 20°C with 50% relative humidity and a 12-h light:dark cycle. All mice had *ad libitum* access to standard rodent chow and filtered water. The mice were acclimated for 1 wk and randomly divided into four groups (5 mice per group): Control, anti-control (antibiotics only), PBS (PBS after antibiotics), and FN (*F. nucleatum* after antibiotics). All mice (except control) were treated with a cocktail of broad-spectrum antibiotics (0.2 g/L ampicillin, 0.1 g/L vancomycin, 0.2 g/L neomycin, and 0.2 g/L metronidazole) in their drinking water for 3 wk to establish flora-deficient status. After 3 wk, the mice were administered 10⁹ CFU *F. nucleatum* or the same dose of PBS by oral gavage every 2 d for 6 wk. At the end of the experiments, mice were anaesthetized with chloroform and euthanized by CO₂ gas to permit collection of biomaterials. All experimental procedures were performed with the approval of the Animal Experimentation Ethics Committee of Kosin University.

**F. nucleatum quantification**

Stool samples were collected from all mice once a week to assess the flora-deficient status and to compare the levels of total bacteria and *F. nucleatum*. For this, total DNA was isolated using the GeneAll Exgene Stool DNA mini kit (GeneAll Biotechnology Co. Seoul, Korea) according to the manufacturer’s instructions. After quantification
and confirmation of purity using the Exgene Stool DNA mini kit (GeneAll, Seoul, Korea), an aliquot of total DNA (1 mg) was used as a template to be mixed with TB Green Premix Ex Taq II (Takara Bio, Shiga, Japan). The primers used for amplification were: F. nucleatum 5’-CGAGGAACCTTACCAGCGTT-3’ (F) and 5’-CCCAACATCTCAGGACACAGCA-3’ (R); total bacteria 5’-GTGSTGCAYGGYTGTCGTCA-3’ (F) and 5’-ACGTCRCCMACCATCCTCCTCTC-3’ (R); and GAPDH 5’-TGGCCTTCCGTGTTCCTAC-3’ (F) and 5’-GAG-TTGCTGTTGAAGTCGCA-3’ (R). All reactions were performed in triplicate in a 7300 Real-time polymerase chain reaction (PCR) system (Applied Biosystems, Waltham, MA, USA).

**Assay of ex vivo NK cell activity**

At necropsy, whole blood was collected from the heart and placed in sodium heparin-coated tubes for subsequent isolation of plasma. NK cell activity was then assessed (in triplicate) using a Murine NK activity kit (ATGen Co. Ltd., Seoul, Korea) according to the manufacturer’s instructions. The absorbance generated for each sample reflected the relative amount of NK cell activity in the sample.

**Immunohistochemical analyses of intestinal CD3 and NKp46 cells**

Murine colon tissues were collected and placed in 10% buffered formalin overnight for fixing. Sections 4-μm thick were then prepared for immunohistochemical (IHC) staining using an automated immunostainer (Bond-MAX, Leica, Buffalo Grove, IL, USA). Antibodies against mouse CD3 (rabbit polyclonal, Dako, Agilent Technologies, city, state) and NKp46 (rabbit polyclonal, R&D Systems, Minneapolis, MN, USA) were used. Stained samples were then evaluated by light microscopy and immuno-activity was assessed. The CD3+ or NKp46+ cells were counted in five different fields (total = 500 counted cells) under 400 × magnification; cell counts were then converted to percentages for data presentation.

**Biochemical assays**

Plasma levels of pro-inflammatory interleukin (IL)-6, -1β, -18, and -12p70, and tumor necrosis factor (TNF)-α were measured (in duplicate) using commercial ELISA kits (Mouse IL-6 Uncoated ELISA, Mouse IL-18 Platinum ELISA, Mouse IL-1β Uncoated ELISA, Mouse IL-12p70 Platinum ELISA and Mouse TNF-α Uncoated ELISA; all Invitrogen). All experimental steps were performed at room temperature and in duplicate. Samples were quantified by spectrophotometry at 450 nm. The sensitivity levels of the kits were 4-500 pg/mL for IL-6, 8-1000 pg/mL for IL-1β, 31.2-2000 pg/mL for IL-18, 15.6-1000 pg/mL for IL-12p70, and 8-1000 pg/mL for TNF-α.

**Statistical analysis**

Each experiment was repeated at least three times. Data are expressed as means ± SD from each independent experiment. A Student’s t-test was performed for continuous variables; outcomes with P ≤ 0.05 were considered statistically significant. Statistical analyses were performed using SPSS Statistics software (v. 23.0, IBM, Armonk, NY, USA).

**RESULTS**

**Cytotoxic effect of F. nucleatum, P. anaerobius, and P. micra on NK cells in vitro**

The effects of various gut microbiota species on NK cell survival were first assessed. Here, F. nucleatum, P. anaerobius, and P. micra -all known to be associated with CRC—were cultured with NK cells for 24 or 48 h. To identify optimal amounts of gut microbiome species affecting NK cells, experiments with each were carried out at 100:1, 250:1, or 500:1 MOI. As shown in Figure 1, NK cell counts were decreased in co-cultures with F. nucleatum, P. anaerobius, and P. micra. The results were remarkable in co-cultures at both 24 and 48 h; however, F. nucleatum most markedly decreased NK cell counts after 48 h. Therefore, F. nucleatum was selected for further study here as the representative microbiome species for use in subsequent in vivo studies.

**NK cell activity decreased in mice treated with F. nucleatum**

To test whether F. nucleatum could reduce the activity of NK cells in mice, the animals were divided into four groups (5 mice per group): Control, anti-control, PBS and FN (Figure 2A). To establish flora-deficient status, mice were treated with a cocktail of broad-spectrum antibiotics for 3 wk. Confirmation of flora-deficiency was then
Figure 1 Effects of *Fusobacterium nucleatum*, *Peptostreptococcus anaerobius*, and *Parvimonas micra* on natural killer cells in vitro.

Natural killer 92 cells were cultured for 24 or 48 h with each organism at a multiplicity of infection of 100:1, 250:1 or 500:1. Post-incubation, viability in the cultures was assessed using trypan blue staining. A: *Fusobacterium nucleatum*; B: *Peptostreptococcus anaerobius*; C: *Parvimonas micra*. *F. nucleatum*: *Fusobacterium nucleatum*; *P. anaerobius*: *Peptostreptococcus anaerobius*; *P. micra*: *Parvimonas micra*.

Figure 2 Experimental design. A: Mice were divided into four groups: Control, anti-control (antibiotics only), phosphate-buffered saline (PBS) (PBS after antibiotics), and *Fusobacterium nucleatum* (*F. nucleatum*) (*F. nucleatum* after antibiotics). The mice were treated with broad-spectrum antibiotics for 3 wk (except control), *F. nucleatum* was introduced to mice every 2 d for 6 wk by oral gavage; B: After treatments, the levels of total gut bacteria (left) and *F. nucleatum* (right) were evaluated; C: After administration of *F. nucleatum*, levels of total bacteria (left) and *F. nucleatum* (right) in mice were again evaluated. Data are expressed as means ± SD of three independent experiments. PBS: Phosphate-buffered saline.

assessed by quantitative PCR analyses of stool samples; the data confirmed that the levels of total bacteria and *F. nucleatum* were decreased (Figure 2B). At that point, *F. nucleatum* was re-introduced by oral gavage to the flora-deficient mice every 2 d for 6 wk. Analyses of their stools showed that levels of total bacteria and *F. nucleatum* gradually increased and then attained a plateau (Figure 2C).

The body weights of the mice were checked every week and compared. The weights of PBS and FN mice were lower compared to those of the control and anti-control groups after oral gavage; however, the differences were not significant (Figure 3A). At sacrifice (i.e., after 6 wk of gavage treatments), the mice were euthanized and the entire colon of each was isolated, longitudinally-opened, and examined. No significant
Figure 3 Body weight, colon length, and mucosal surface among the experimental groups. A: Weights of mice; B: Colon length and mucosal surface. PBS: Phosphate-buffered saline; FN: F. nucleatum.

differences in colonic length or colonic mucosal surface were found between the groups (Figure 3B).

To evaluate the activity of NK cells in situ, levels of interferon-gamma (IFN-γ) in the blood of each mouse was evaluated. The data indicated that the activity of NK cells in the FN group was significantly lower than in the control, anti-control, and PBS mice (Figure 4).

**Local NK cell numbers in the gut decreased in mice treated with F. nucleatum**

Using IHC staining, the intestinal tract of the mice was evaluated for the presence of NK cells. The data indicate that the levels of CD3+ cells were significantly lower in the anti-control, PBS, and FN mice than in the control mice (Figure 5). The levels of NKp46+ cells were lower in the FN group than in the control group, although the difference was not significant.

**F. nucleatum treatments resulted in increased plasma pro-inflammatory cytokine levels**

As shown in Figure 6, plasma levels of select pro-inflammatory cytokines were also evaluated at the end of the treatment regimens. The data indicated that circulating levels of IL-1β and TNF-α in the FN mice were significantly higher than in the control mice; values in the anti-control and PBS groups were not significantly higher than in the controls. Plasma levels of IL-6, IL-18, and IL-12p70 in the FN mice were not significantly higher than in the control. In addition, the values in the anti-control and PBS groups were not significantly changed compared to the control group.

**DISCUSSION**

Emerging evidence has shown a role for the gut microbiome, especially *F. nucleatum*, in cancer biology. Although *F. nucleatum*, a common bacterial resident in the oral cavity, has been shown to be involved in the proliferation of CRC cells and tumor development, data on how the Fusobacteria engage in the development of CRC are lacking. This study showed that a high abundance of *F. nucleatum* in the gastrointestinal tract reduced the activity of NK cells and that such outcomes might be associated with a concurrent increase in circulating levels of some pro-inflammatory cytokines, including IL-1β and TNF-α in these hosts. These findings suggest that increases in *F. nucleatum* in the gastrointestinal tract could be a factor in disrupting how the immune system prevents development of CRC.

The importance of the gut microbiome in immunity/inflammation has been more clearly elucidated in the past two decades. In a healthy state, the host immune system responds to intestinal microbiome strictly confined to the mucosal surface [18]. The mucus layer, epithelial cells, immunoglobulin A, dendritic cells, and T-cells comprise the mucosal barrier; these prevent the exposure and passage of gut microbiome to the
Kim YJ et al. *F. nucleatum* and NK cells

**Figure 4** Blood levels of interferon-gamma. To indirectly evaluate the activity of natural killer cells, whole blood from each mouse was collected at necropsy and levels of interferon-gamma evaluated by ELISA. Data are expressed as means ± SD of three independent experiments. Value significantly different at *P* < 0.05. IFN-γ: Interferon-gamma; PBS: Phosphate-buffered saline; FN: *F. nucleatum*.

**Figure 5** Intestinal levels of CD3 and NKp46 cells. A: CD3⁺ cells; B: NKp46⁺ cells. Data are expressed as means ± SD of three independent experiments. Value significantly different at *P* < 0.05. NK: Natural killer; PBS: Phosphate-buffered saline; FN: *F. nucleatum*.

gut-associated lymphoid tissue[19]. When the maintenance of tissue homeostasis is destroyed, translocating bacteria into the mucosal tissue causes a local (and systemic) effect on inflammatory cells, *i.e.*, tissue inflammatory monocytes can respond to microbial-derived ligands by producing prostaglandin E₂, which limits neutrophil activation and tissue damage[20].

*F. nucleatum*, whose presence has been proposed to correlate with CRC, can induce inflammation and suppress host immunity. There is increased evidence that *F. nucleatum* modulates immune cells in the CRC microenvironment and promotes intestinal tumorigenesis[21]. *F. nucleatum* can also stimulate autophagic pathways and alter chemotherapeutic responses of patients[22]. The current study focused on the impact of *F. nucleatum* upon gastrointestinal tract immune cells, especially NK cells. This study found that *F. nucleatum* could reduce local NK cell counts and decrease the activity of NK cells in mice. Normally, NK cell activity is controlled by a balance of various signals that are delivered to the cells via inhibitory and activating NK cell receptors[23]. One study revealed that the ability of NK cells to kill tumors was inhibited by hemagglutinating *F. nucleatum* strains and that *F. nucleatum* inhibited immune cell activity by specifically targeting the inhibitory receptor TIGIT via the Fap2 protein[8]. Although the present study did not investigate the detailed mechanism for the observed inhibitory effects of *F. nucleatum* on the activity of NK cells in mice, the findings suggest that the gut microbiome could play an inhibitory role.

NK cells usually present as CD56⁻CD3⁺ cells and can be categorized into CD3⁻CD56⁺CD16⁺ and CD3⁻CD56⁺CD16⁻ cell classes. CD56⁺CD16⁺ cells appear to have more cytotoxic activity, while CD56⁺CD16⁻ cells produce high levels of cytokines including IFN-γ and TNF-α[24]. The activation and inhibition of NK cells are induced by an interplay among the cells’ activating and inhibitory receptors[25]. NKp46 is expressed on NK cells in the tumor bed and is a major determinant of NK cell function[26]. In the current study, levels of CD3⁺ cells significantly decreased after antibiotic treatment and NKp46⁺ cells decreased after administration of *F. nucleatum*, although the difference
Kim YJ et al. F. nucleatum and NK cells

Figure 6 Plasma pro-inflammatory cytokine levels. A: Interleukin (IL)-1β; B: Tumor necrosis factor-α; C: IL-6; D: IL-18; E: IL-12p70. Data are expressed as means ± SD of three independent experiments. Value significantly different at *P < 0.05. PBS: Phosphate-buffered saline; FN: F. nucleatum; IL: Interleukin; TNF-α: Tumor necrosis factor-α.

was not significant. Based on these results, it is thought that the microenvironment change after antibiotic treatment could affect these alterations, and the administration of F. nucleatum might decrease NK cell number.

Several inflammatory cytokines (including TNF-α, IL-6, IL-18, and IL-1β) are known to be involved in the initiation and progression of cancers[27], and could modulate the activation of NK cells. TNF-α can induce DNA damage through reactive oxygen and nitrogen species, IL-18 can induce the production of angiogenic and tumor growth stimulating factors, IL-6 can induce oxidative stress and promote early tumorigenesis, and IL-1β can promote neo-angiogenesis and evoke antiapoptotic signaling in tumor cells[28-30]. It is plausible that any changes in the expression in one or more of these could modulate tumor growth/survival in situ by also modulating the activation of NK cells[31]. For example, IL-12 can enhance the activity of NK cells and CD8+ T-lymphocytes, and so is expected to impart anti-tumor activity[32,33]. In this study, it was seen that circulating levels of IL-1β and TNF-α (but not IL-6, IL-18, or IL-12p70) were significantly increased after administration of F. nucleatum to mice. Further studies are needed to determine if these changes directly/indirectly impact the activity of NK cells themselves in hosts.

This study has some limitations. First, whether decreased NK cell activity induces the development of CRC was not assessed. Further studies including the association between NK cell activity and CRC could strengthen the results. Second, the pro-inflammatory cytokine levels were not evaluated in NK92 cells and in colonic tissues treated with F. nucleatum. Therefore, changes in plasma pro-inflammatory cytokine levels in NK92 cells and in colonic tissues treated with F. nucleatum were not confirmed.
Figure 7 A possible mechanism. High levels of *F. nucleatum* in the gastrointestinal tract induce an increase in plasma pro-inflammatory cytokines, which reduces natural killer cell activity. IL: Interleukin; TNF-α: Tumor necrosis factor-α; NK: Natural killer.

**CONCLUSION**

In summary, the current study identified that high levels of *F. nucleatum* in the gastrointestinal tract reduced NK cell activity in mice and suggests insights on how NK cell activity was affected, *i.e.*, *F. nucleatum* induced systemic pro-inflammatory responses in the hosts. Based on these findings, we suggest a possible mechanism by which high levels of *F. nucleatum* in the gastrointestinal tract induce an increase in plasma pro-inflammatory cytokines, which reduces NK cell activity (*Figure 7*). Our findings illustrate another potential means by which gut microbiome can influence NK cells which, in turn could impact the development of CRC.

**ARTICLE HIGHLIGHTS**

**Research background**

Gut microbial dysbiosis contributes to the development and progression of colorectal cancer (CRC). Natural killer (NK) cells are involved in early defense mechanisms to kill infective pathogens and tumor cells by releasing chemokines and cytokines.

**Research motivation**

This study was designed to better understand the relationship between the gut microbiome and CRC.

**Research objectives**

The objective of this study was to identify associations between gastrointestinal tract *Fusobacterium nucleatum* (*F. nucleatum*) levels and NK cell activity.

**Research methods**

*In vitro* experiments were performed on NK cells treated with *F. nucleatum*, *Peptostreptococcus anaerobius*, and *Parvimonas micra* to identify the effects of gut microbiome species on NK cells. After 24 and 48 h of treatment, NK cell counts were measured. In parallel studies, C57BL/6 mice were given broad-spectrum antibiotics in their drinking water to reduce resident gut flora. After 3 wk, the mice received the various bacterial species or phosphate-buffered saline *via* oral gavage every 2 d for 6 wk. At the study end, blood samples were acquired to perform NK cell activity assessment and cytokine analysis. Intestinal tissues were collected and analyzed *via* immunohistochemistry (IHC).

**Research results**

After 3 wk of broad-spectrum antibiotic treatment, levels of total bacteria and *F. nucleatum* were markedly decreased in mice. *F. nucleatum* by gavage significantly decreased NK cell activity relative to the activities of cells from mice treated with antibiotics only and phosphate-buffered saline. The administration of *F. nucleatum* decreased the proportion of NK46<sup>+</sup> cells based on IHC staining and increased the production of interleukin-1β and tumor necrosis factor-α.
Research conclusions
High levels of *F. nucleatum* in the gastrointestinal tract reduced NK cell activity in mice, and the decrease in NK cell activity might be affected by increased pro-inflammatory cytokines after *F. nucleatum* treatment.

Research perspectives
Based on these findings, we suggest that increases in *F. nucleatum* in the gastrointestinal tract could be a factor in disrupting how the immune system prevents development of CRC.

REFERENCES

1. Mima K, Nishihara R, Qian ZR, Cao Y, Suzuki Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M, Kostic AD, Giannakis M, Bullman S, Milner DA, Baba H, Giovannucci EL, Giarray LA, Freeman GJ, Dranoff G, Garrett WS, Huttoncower C, Meyerson M, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 2016; 65: 1973-1980 [PMID: 26311717 DOI: 10.1136/gutjnl-2015-310101]

2. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. *Nat Rev Microbiol* 2014; 12: 661-672 [PMID: 25198138 DOI: 10.1038/nrmicro3344]

3. Irrazabal T, Belcheva A, Girardin SE, Martin A, Philpott DJ. The multifaceted role of the intestinal microbiota in colon cancer. *Mol Cell* 2014; 54: 309-320 [PMID: 24766895 DOI: 10.1016/j.molcel.2014.03.039]

4. Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsai H, Dong Y, Zhang N, He Y, Kang Q, Cao L, Wang K, Zhang J, Liang Q, Yu J, Sung JJ. Gut mucosal microbiome across stages of colorectal carcinogenesis. *Nat Commun* 2015; 6: 8727 [PMID: 26515465 DOI: 10.1038/ncomms9727]

5. Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, Tang L, Zhao H, Stenvang J, Li Y, Wang X, Xu X, Chen N, Wu WK, Al-Aama J, Nielsen HJ, Kiilerich P, Jensen BA, Yau TO, Lan Z, Jia H, Li J, Xiao L, Lam TY, Ng SC, Cheng WQ, Chan FK, Yang H, Madsen L, Datz C, Tilg H, Wang J, Brünner N, Kristiansen K, Arumugam M, Sung JJ. Metagenomic analysis of faecal microbiome as a tool towards non-invasive biomarkers for colorectal cancer. *Gut* 2017; 66: 70-78 [PMID: 26408646 DOI: 10.1136/gutjnl-2015-309800]

6. Abed J, Engård JE, Zamir G, Faroja M, Almogy G, Grenov A, Sol A, Ao R, Pikarsky E, Atlan KA, Mellul A, Chau shu S, Manson AL, Earl AM, Ou N, Brennan CA, Garrett WS, Bachrach G. Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GaINac. *Cell Host Microbe* 2016; 20: 215-225 [PMID: 27512904 DOI: 10.1016/j.chom.2016.07.006]

7. Yang Y, Weng W, Peng J, Hong L, Yang L, Toyama Y, Gao R, Liu M, Yin M, Pan C, Li H, Guo B, Zhou Q, Wei Q, Moyer MP, Wang P, Cai S, Goel A, Qin H, Ma Y. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-kB, and Up-regulating Expression of MicroRNA-21. *Gastroenterology* 2017; 152: 851-866.e24 [PMID: 27876571 DOI: 10.1053/j.gastro.2016.11.018]

8. Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, Enk J, Bar-On Y, Stanietsky-Kayan N, Coppenhagen-Glazer S, Shussman N, Almogy G, Cuapio A, Hofer E, Meverdach T, Tabib A, Ortenberg R, Markel G, Mikilic K, Jonjic S, Brennan CA, Garrett WS, Bachrach G, Mandelboim O. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. *Immunity* 2015; 42: 344-355 [PMID: 25860274 DOI: 10.1016/j.immuni.2015.02.010]

9. Nosho K, Suzuki Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, Kanno S, Yamamoto I, Ishigami I, Kagarashi H, Maruyama R, Igarashi H, Yamamoto I, Shinomura Y. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. *World J Gastroenterol* 2016; 22: 557-566 [PMID: 26811607 DOI: 10.3748/wjg.v22.i2.557]

10. Huyhn T, Kapur RV, Kaplan CW, Cacalano A, Kinder Haake S, Shi W, Sieling P, Jewett A. The role of aggregation in Fusobacterium nucleatum- induced immune cell death. *J Endod* 2011; 37: 1531-1535 [PMID: 22000457 DOI: 10.1016/j.joen.2011.06.034]

11. Shenker BJ, Datar S. Fusobacterium nucleatum inhibits human T-cell activation by arresting cells in the mid-G1 phase of the cell cycle. * Infect Immun* 1995; 63: 4830-4836 [PMID: 7591143 DOI: 10.1128/IAI.63.12.4830-4836.1995]

12. Kiessling R, Klein E, Pross H, Wizhell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. *Eur J Immunol* 1975; 5: 117-121 [PMID: 1086218 DOI: 10.1002/eji.1830050209]

13. Bryceson YT, Chiang SC, Darmanin S, Fauriat C, Schlums H, Theorell J, Wood SM. Molecular mechanisms of natural killer cell activation. *J Innate Immun* 2011; 3: 216-226 [PMID: 21454962 DOI: 10.1159/000325265]

14. Imai K, Matsu yama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. *Lancet* 2000;
Kim YJ et al. F. nucleatum and NK cells

DOI: 10.1016/S0140-6736(00)03231-1

15 Kondor A, Cong Y, Duck W, Borlaza R, Elson CO. Tight mucosal compartmentation of the murine immune response to antigens of the enteric microbiota. Gastroenterology 2006; 130: 2050-2059

DOI: 10.1053/j.gastro.2006.02.055

19 Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014; 157: 121-141

DOI: 10.1016/j.cell.2014.03.011

20 Schreiber S, Rosenstiel P, Albrecht M, Hampe J, Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet 2005; 6: 376-388

DOI: 10.1038/ng1607

21 Brennan CA, Garrett WS. Gut Microbiota, Inflammation, and Colorectal Cancer. Anna Rev Microbiol 2016; 70: 395-411

DOI: 10.1146/annurev-micro-102215-095513

22 Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N, Chen Y, Chen H, Hong J, Zou W, Fang JY. Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy. Cell 2017; 170: 548-563.e16

DOI: 10.1016/j.cell.2017.07.008

23 Koch J, Steinle A, Watzl C, Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 2013; 34: 182-191

DOI: 10.1016/j.it.2013.01.003

24 Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990; 76: 2421-2438

DOI: 10.1182/blood.V76.12.2421.bloodjournal76122421

25 Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640

DOI: 10.1016/s1471-4906(01)02060-9

26 Chretien AS, Devillier R, Fauriat C, Orlanducci F, Harbi S, Le Roy A, Rey J, Bouvier Borg G, Gautherot E, Hamel JF, Ifrah N, Lacombe C, Cornillet-Lefebvre P, Delaunay J, Toubert A, Arnoulet C, Vey N, Blaise D, Olive D. Nkp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML. Oncoimmunology 2017; 6: e1307491

DOI: 10.1080/2162402X.2017.1307491

27 Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res 2014; 2014: 149185

DOI: 24901008

28 Palma G, Barbieri A, Bimonte S, Palli M, Zappavigna S, Caraglia M, Ascieto PA, Ciliberto G, Arra C. Interleukin 18: friend or foe in cancer. Biochim Biophys Acta 2013; 1836: 290-303

DOI: 24120982

29 Murata M, Thanan R, Ma N, Kawanishi S. Role of nitrative and oxidative DNA damage in inflammation-related carcinogenesis. J Biomed Biotechnol 2012; 623019

DOI: 22363173

29 Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T. Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 2008; 27: 378-386

DOI: 10.1038/sj.onc.1210648

30 Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. Biofactors 2010; 36: 274-288

DOI: 10.1002/biof.107

31 Tugues S, Burkhard SH, Ols I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher B. New insights into IL-12-mediated tumor suppression. Cell Death Differ 2015; 22: 237-246

DOI: 25190142

32 Lu X. Impact of IL-12 in Cancer. Curr Cancer Drug Targets 2017; 17: 682-697

DOI: 10.2174/1568009617666170427102729
